GlobeNewswire Inc.Apr 22, 1:00 PM ETNeutral
Developing divesiran (SLN124) in Phase II trials; early-stage with uncertain competitive advantage, dependent on durability and safety data versus other iron-modulating therapies.
Silence Therapeutics Plc American Depository Share news
$11.20+0.18%
Close Sep 28, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Silence Therapeutics Plc American Depository Share
No recent articles focused on Silence Therapeutics Plc American Depository Share.
Also mentions SLN
Articles that tag SLN but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology